Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Live Nation Entertainment, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while Live Nation Entertainment, Inc. trades at $182.67 (market cap $41.84B). The key difference: Alnylam Pharmaceuticals, Inc. and Live Nation Entertainment, Inc. are close in size by market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | LYV | |
|---|---|---|
Market Cap | $39.89B | $41.84B |
Sector | Health | Industrials |
52-Week High | $491.22 | $186.59 |
52-Week Low | $278.09 | $125.61 |
Enterprise Value | $38.15B | $43.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Live Nation (LYV) trades at $179.79, down 1.53% today, with strong analyst support (88.6% buy ratings) and a $200.20 consensus price target. The stock shows bullish technical signals despite recent earnings misses, with revenue growth to $25.2B in 2025 but net margins narrowing to 1.96%. Recent news highlights strong concert demand and strategic initiatives, though legal challenges and cost pressures remain concerns.
Outlook remains positive based on analyst consensus and projected cash flow growth, but investors face risks from volatile earnings, high debt levels, and regulatory scrutiny. The stock's elevated P/E of 117.5 reflects growth expectations that must materialize to justify current valuations amid competitive and economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
